natgillin/translations-raw huggingface dataset:
Splenomegaly was reported to be related to filgrastim therapy in &lt; 3% of patients.
Poročali so, da je splenomegalija pri &lt; 3% bolnikov povezana z zdravljenjem s filgrastimom.
Sprimeo HCT was studied in a placebo-controlled trial including 2,762 hypertensive patients with diastolic blood pressure ≥ 95 mmHg and &lt; 110 mmHg (mean baseline blood pressure of 153.6/99.2 mmHg).
Zdravilo Sprimeo HCT so proučevali v preskušanju, kontroliranem s placebom; v katerem je bilo vključenih 2.762 hipertenzivnih bolnikov z diastoličnim krvnim tlakom ≥ 95 mmHg in &lt; 110 mmHg (povprečna izhodiščna vrednost krvnega tlaka je bila 153,6/99,2 mmHg).
Sprimeo is not recommended in patients with severe renal impairment (GFR &lt; 30 ml/min/1.73 m2).
Pri bolnikih s hudo okvaro ledvic (GFR &lt; 30 ml/min/1,73 m2) uporaba zdravila Sprimeo ni priporočena.
Sprimeo is not recommended in patients with severe renal impairment (glomerular filtration rate (GFR) &lt; 30 ml/min/1.73 m2).
Pri bolnikih s hudo okvaro ledvic (s hitrostjo glomerulne filtracije (GFR) &lt; 30 ml/min/1,73 m2) uporaba zdravila Sprimeo ni priporočena.
Sprimeo may be used alone or in combination with other antihypertensive agents with the exception of use in combination with angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt; 60 ml/min/1.73 m2) (see sections 4.3, 4.4 and 5.1).
Zdravilo Sprimeo se lahko jemlje samostojno ali v kombinaciji z drugimi učinkovinami za zniževanje krvnega tlaka, razen v kombinaciji z zaviralci encima angiotenzinske konvertaze (zaviralci ACE) ali zaviralci angiotenzinskih receptorjev II pri bolnikih s sladkorno boleznijo ali okvaro ledvic (s hitrostjo glomerulne filtracije (GFR) &lt; 60 ml/min/1,73 m2) (glejte poglavja 4.3, 4.4 in 5.1).
SRH area &gt; 25 mm²
površina SRH &gt; 25 mm²
SRH area &gt; 25 mm²; MN titer ≥ 1:40;
površina SRH &gt; 25 mm²; titer MN ≥1:40;
SRH area &gt; 25 mm²; MN titer ≥1:40;
površina SRH &gt; 25 mm²; titer MN ≥1:40;
SRH area &gt; 25 mm²; MN titre ≥ 1:40;
površina SRH &gt; 25 mm²; titer MN ≥1:40;
Standard criteria donor organs were defined as organs from a living donor, or a deceased donor with anticipated cold ischemia time of &lt; 24 hours and not meeting the definition of extended criteria donor organs.
Darovani organ po standardnih kriterijih je opredeljen kot organ živega ali umrlega darovalca, pri katerem pričakovani čas hladne ishemije ne presega 24 ur in pri katerem niso izpolnjeni pogoji razširjenih kriterijev za darovani organ.
Staphylococcus aureus (CP8) strain SP 140 inactivated, expressing slime associated antigenic complex (SAAC) .............…………………………………………… &gt; 50 RED80**
Staphylococcus aureus (CP8) sev SP 140 inaktiviran, izraža z antigenskim kompleksom povezano izločanje sluzi (SAAC)...................…………………………………………… &gt; 50 RED80
Staphylococcus aureus (CP8) strain SP 140 inactivated, expressing slime associated antigenic complex (SAAC)................................................................................................................ &gt; 50 RED80**
Staphylococcus aureus (CP8) sev SP 140 inaktiviran, izraža z antigenskim kompleksom povezano izločanje sluzi (SAAC)...................…………………………………………… &gt; 50 RED80
Starting dose of 600 mg, which can be titrated up to a maximum of 1,000/1,200 mg (1,000 mg for patients weighing &lt; 75 kg and 1,200 mg for patients weighing ≥ 75 kg) if well tolerated.
Začetni odmerek znaša 600 mg in če ga bolniki dobro prenašajo, ga je mogoče povečevati do največ 1.000–1.200 mg (1.000 mg za bolnike s telesno maso &lt; 75 kg in 1.200 mg za bolnike s telesno maso ≥ 75 kg).
STARTMRK (multi-centre, randomised, double-blind, active-control study) evaluated the safety and anti-retroviral activity of raltegravir 400 mg twice daily vs. efavirenz 600 mg at bedtime, in a combination with emtricitabine (+) tenofovir, in treatment-naïve HIV-infected patients with HIV RNA &gt; 5,000 copies/ml.
V študiji STARTMRK (multicentrični, randomizirani, dvojno slepi, z zdravilno učinkovino nadzorovani študiji) so ocenjevali varnost in protiretrovirusno delovanje 400 mg raltegravirja dvakrat na dan v primerjavi s 600 mg efavirenza pred spanjem v kombinaciji z emtricitabinom (+) tenofovirjem pri še nezdravljenih bolnikih, okuženih s HIV in HIV RNA &gt; 5.000 kopij/ml.
Statistically greater proportions of patients achieved blood pressure control ( &lt; 140/90 mmHg) with Copalia HCT (71%) compared to each of the three dual combination therapies (45-54%) (p &lt; 0.0001).
Krvni tlak je uspelo uravnati ( &lt; 140/90 mmHg) statistično večjemu deležu bolnikov, ki so jemali zdravilo Copalia HCT (71 %) v primerjavi s tistimi, ki so jemali katero od treh kombinacij s po dvema zdraviloma (45-54 %) (p &lt; 0,0001).
Statistically greater proportions of patients achieved blood pressure control ( &lt; 140/90 mmHg) with Dafiro HCT (71%) compared to each of the three dual combination therapies (45-54%) (p &lt; 0.0001).
Krvni tlak je uspelo uravnati ( &lt; 140/90 mmHg) statistično večjemu deležu bolnikov, ki so jemali zdravilo Dafiro HCT (71 %) v primerjavi s tistimi, ki so jemali katero od treh kombinacij s po dvema zdraviloma (45 -54 %) (p &lt; 0,0001).
Statistically greater proportions of patients achieved blood pressure control ( &lt; 140/90 mmHg) with Dafiro HCT (71%) compared to each of the three dual combination therapies (45-54%) (p &lt; 0.0001).
Krvni tlak je uspelo uravnati ( &lt; 140/90 mmHg) statistično večjemu deležu bolnikov, ki so jemali zdravilo Dafiro HCT (71 %) v primerjavi s tistimi, ki so jemali katero od treh kombinacij s po dvema zdraviloma (45-54 %) (p &lt; 0,0001).
Statistically greater proportions of patients achieved blood pressure control ( &lt; 140/90 mmHg) with Imprida HCT (71%) compared to each of the three dual combination therapies (45-54%) (p &lt; 0.0001).
Krvni tlak je uspelo uravnati ( &lt; 140/90 mmHg) statistično večjemu deležu bolnikov, ki so jemali zdravilo Imprida HCT (71 %) v primerjavi s tistimi, ki so jemali katero od treh kombinacij s po dvema zdraviloma (45-54 %) (p &lt; 0,0001).
Statistically significant (p &lt; 0.001) changes from baseline HbA1c relative to placebo of -0.57% and -0.70% were observed for 100 mg and 300 mg, respectively (see sections 4.2 and 4.8).
Pri bolnikih so opazili statistično značilno (p &lt; 0,001) spremembo odstotka HbA1c od izhodiščne vrednosti glede na placebo za -0,57% oziroma -0,70% pri uporabi odmerka 100 mg oziroma 300 mg (glejte poglavji 4.2 in 4.8).
Statistically significant (p &lt; 0.001) changes from baseline HbA1c relative to placebo of -0.57% and -0.70% were observed for 100 mg once daily and 300 mg once daily, respectively (see sections 4.2 and 4.8).
Pri bolnikih so opazili statistično značilno (p &lt; 0,001) spremembo odstotka HbA1c od izhodiščne vrednosti glede na placebo za -0,57% oziroma -0,70% pri uporabi odmerka 100 mg oziroma 300 mg enkrat na dan (glejte poglavji 4.2 in 4.8).
Statistically significant differences are marked (*p &lt; 0.05) for between treatment comparisons (4 mg zoledronic acid vs. placebo)
Označene so statistično značilne razlike (*p &lt; 0,05) za primerjavo med zdravljenjema (4 mg zoledronske kisline v prim. s placebom)
Statistically significant differences are marked (*p &lt; 0.05) for between treatment comparisons (4 mg zoledronic acid vs. placebo)
Statistično značilne razlike so označene (*p &lt; 0,05) za primerjavo med zdravljenji (4 mg zoledronska kislina v primerjavi s placebom)
Statistically significant differences from placebo (p &lt; 0.05) were observed for improvements in the total signs and symptoms score for all dose groups compared to placebo.
V vseh odmernih skupinah so ugotovili statistično pomembno (p &lt; 0,05) razliko izboljšanja celotne ocene simptomov in znakov v primerjavi s placebom.
Statistically significant improvements in haemoglobin levels were observed with tocilizumab compared with DMARDs (p &lt; 0.0001) at week 24.
Po 24 tednih so pri tocilizumabu v primerjavi z imunomodulirajočimi antirevmatičnimi zdravili ugotovili statistično značilno izboljšanje koncentracije hemoglobina (p &lt; 0,0001).
Statistically significant improvements in spinal mobility as assessed by BASMI (Bath Ankylosing Spondylitis Metrology Index) and in physical function as assessed by the BASFI were demonstrated in Simponi 50 mg-treated patients as compared to placebo-treated patients (p &lt; 0.0001).
Pri bolnikih, zdravljenih z zdravilom Simponi 50 mg, so v primerjavi s tistimi, ki so prejemali placebo, dokazali statistično značilno izboljšanje gibljivosti hrbtenice, merjene z BASMI (Bath Ankylosing Spondylitis Metrology Index), in telesne funkcije, merjene z BASFI (p &lt; 0,0001).
Statistically significant increases in femoral neck BMD and total hip BMD (p &lt; 0,001) were observed after 12 months.
Po 12 mesecih so opazili statistično značilno povečanje mineralne kostne gostote v vratu stegnenice in celotne mineralne kostne gostote v kolku (p &lt; 0,001).
Statistically significant responses in DAS28 were also observed at weeks 14 and 24 (p &lt; 0.05).
Statistično značilen odziv na zdravljenje, merjen z DAS28, so opazili tudi v 14. in 24. tednu (p &lt; 0,05).
Steady-state pharmacokinetics of tenofovir were evaluated in 8 HIV-1 infected adolescent patients (aged 12 to &lt; 18 years) with body weight ≥ 35 kg and in 23 HIV- 1 infected children aged 2 to &lt; 12 years.
Farmakokinetične lastnosti tenofovirja v stanju dinamičnega ravnovesja so bile ocenjene pri 8 adolescentih s HIV–1 (starih od 12 do &lt; 18 let) s telesno maso ≥ 35 kg in pri 23 otrocih s HIV–1, starih od 2 do &lt; 12 let.
Steady-state pharmacokinetics of tenofovir were evaluated in 8 HIV-1 infected adolescent patients (aged 12 to &lt; 18 years) with body weight ≥ 35 kg and in 23 HIV-1 infected children aged 2 to &lt; 12 years.
Farmakokinetične lastnosti tenofovirja v stanju dinamičnega ravnovesja so bile ocenjene pri 8 adolescentih s HIV–1 (starih od 12 do &lt; 18 let) s telesno maso ≥ 35 kg in pri 23 otrocih s HIV–1, starih od 2 do &lt; 12 let.
Steady-state systemic exposure in adolescent patients of bodyweight &gt; 55 kg, as assessed by AUC (0-24), was comparable to that noted for the same doses in the adult population.
Sistemska izpostavljenost zdravilu v stanju dinamičnega ravnovesja, ocenjena s površino pod krivuljo [AUC] (0- 24), je bila pri mladostnikih s telesno maso &gt; 55 kg primerljiva z izpostavljenostjo, ki so jo pri enakih odmerkih ugotovili pri odrasli populaciji.
Stevens-Johnson syndrome, erythema multiforme3, severe rash ( &lt; 1%)
Stevens-Johnsonov sindrom, multiformni eritem3, hud izpuščaj ( &lt; 1 %)
STOCRIN has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts &lt; 50 cells/mm3, or after failure of protease inhibitor (PI) containing regimens.
Uporabe zdravila STOCRIN še niso dovolj preučili pri bolnikih z napredovano boleznijo HIV, to je pri bolnikih z vrednostjo CD4 &lt; 50 celic/mm3, ali po neuspelem zdravljenju z režimom, ki je vključeval zaviralce proteaze (ZP).
Stool consistency in the LIR subgroup as measured by the Bristol stool scale improved in Kodiac 5 versus placebo (p &lt; 0.001) but not in Kodiac 4 (p=0.156).
Konsistenca blata, merjena z Bristolsko lestvico blata (Bristol stool scale), se je v podskupini LIR v Kodiac 5 v primerjavi s placebom izboljšala (p &lt; 0,001), v Kodiac 4 pa ne (p = 0,156).
Stop Glivec until ANC  1.5 x 109/l and platelets  75 x 109/l.
trombocitov &lt; 50 x 109/l
Stop imatinib until ANC ≥ 1.5 x 109/L and platelets ≥ 75 x 109/L.
ANC &lt; 1,0 x 109/L in/ali koncentracija trombocitov
Streptococcus A,B,C,G: S ≤ 0.5 mg/L and R &gt; 0.5 mg/L
Streptococcus A, B, C, G: S ≤ 0,5 mg/l in R &gt; 0,5 mg/l
Streptococcus pneumoniae: S ≤ 0.5 mg/L and R &gt; 0.5 mg/L
Streptococcus pneumoniae: S ≤ 0,5 mg/l in R &gt; 0,5 mg/l
Streptococcus spp. other than S. pneumoniae S  0.25 mg/L and R  0.5 mg/L
Streptococcus spp., razen S. pneumoniae, S  0,25 mg/l in R &gt; 0,5 mg/l
Streptococcus spp. other than S. pneumoniae S  1 mg/l and R &gt; 1 mg/l
Streptococcus spp. z izjemo S. pneumoniae S  1 mg/l in R &gt; 1 mg/l
Stribild met the non-inferiority criteria in achieving HIV-1 RNA &lt; 50 copies/mL when compared to efavirenz/emtricitabine/tenofovir disoproxil fumarate and when compared to atazanavir/ritonavir + emtricitabine/tenofovir disoproxil fumarate.
Zdravilo Stribild je izpolnilo kriterije enakovrednosti pri doseganju HIV-1 RNA &lt; 50 kopij/ml v primerjavi s kombinacijo efavirenza/emtricitabina/dizoproksiltenofovirijevega fumarata in v primerjavi s kombinacijo atazanavirja/ritonavirja + emtricitabina/dizoproksiltenofovirijevega fumarata.
Stribild should be discontinued in patients with confirmed creatinine clearance that falls to &lt; 50 mL/min (since the required dose interval adjustments are not possible using this fixed dose combination tablet) or with decreases in serum phosphate to &lt; 0.32 mmol/L (1.0 mg/dL) (see sections 4.2 and 5.2).
Pri bolnikih s potrjenim padcem očistka kreatinina na &lt; 50 ml/min (ker potrebne prilagoditve intervala odmerjanja s tableto s fiksno kombinacijo odmerkov ni mogoče doseči) ali z zmanjšanjem serumskega fosfata na &lt; 0,32 mmol/l (1,0 mg/dl) je treba zdravljenje z zdravilom Stribild prekiniti (glejte poglavji 4.4 in 5.2).
Strimvelis is not intended for use in patients &gt; 65 years of age, and has not been studied in this age group.
Zdravilo Strimvelis ni namenjeno za uporabo pri bolnikih, starejših od 65 let, in v tej starostni skupini ni raziskano.
Strong complete, basolateral or lateral membranous reactivity in ≥ 10 % of tumour cells
Močno obarvane celotne, bazolateralne ali lateralne membrane pri &gt; 10 % tumorskih celic.
Stronghold 15 mg spot-on for cats and dogs &lt; 2.5 kg Stronghold 30 mg spot-on for dogs 2.6–5.0 kg Stronghold 45 mg spot-on for cats 2.6–7.5 kg Stronghold 60 mg spot-on for cats 7.6–10.0 kg Stronghold 60 mg spot-on for dogs 5.1–10.0 kg Stronghold 120 mg spot-on for dogs 10.1–20.0 kg Stronghold 240 mg spot-on for dogs 20.1–40.0 kg Stronghold 360 mg spot-on for dogs 40.1–60.0 kg
Stronghold 15 mg kožni nanos za mačke in pse &lt; 2,5 kg Stronghold 30 mg kožni nanos za pse 2,6−5,0 kg Stronghold 45 mg kožni nanos za mačke 2,6−7,5 kg Stronghold 60 mg kožni nanos za mačke 7,6−10,0 kg Stronghold 60 mg kožni nanos za pse 5,1−10,0 kg Stronghold 120 mg kožni nanos za pse 10,1−20,0 kg Stronghold 240 mg kožni nanos za pse 20,1−40,0 kg Stronghold 360 mg kožni nanos za pse 40,1−60,0 kg
Stronghold 15 mg spot-on solution for cats and dogs &lt; 2.5 kg Selamectin
Stronghold 15 mg kožni nanos, raztopina za mačke in pse &lt; 2,5 kg selamektin
Stronghold 15 mg spot-on solution for cats and dogs &lt; 2.5 kg Stronghold 30 mg spot-on solution for dogs 2.6–5.0 kg Stronghold 45 mg spot-on solution for cats 2.6–7.5 kg Stronghold 60 mg spot-on solution for cats 7.6–10.0 kg Stronghold 60 mg spot-on solution for dogs 5.1–10.0 kg Stronghold 120 mg spot-on solution for dogs 10.1–20.0 kg Stronghold 240 mg spot-on solution for dogs 20.1–40.0 kg Stronghold 360 mg spot-on solution for dogs 40.1–60.0 kg
Stronghold 15 mg kožni nanos, raztopina za mačke in pse &lt; 2,5 kg Stronghold 30 mg kožni nanos, raztopina za pse 2,6–5,0 kg Stronghold 45 mg kožni nanos, raztopina za mačke 2,6–7,5 kg Stronghold 60 mg kožni nanos, raztopina za mačke 7,6–10,0 kg Stronghold 30 mg kožni nanos, raztopina za pse 5,1–10,0 kg Stronghold 120 mg kožni nanos, raztopina za pse 10,1–20,0 kg Stronghold 240 mg kožni nanos, raztopina za pse 20,1–40,0 kg Stronghold 360 mg kožni nanos, raztopina za pse 40,1–60 kg
Stronghold 15 mg spot-on solution for cats and dogs &lt; 2.5 kg Stronghold 30 mg spot-on solution for dogs 2.6–5.0 kg Stronghold 45 mg spot-on solution for cats 2.6–7.5 kg Stronghold 60 mg spot-on solution for cats 7.6–10.0 kg Stronghold 60 mg spot-on solution for dogs 5.1–10.0 kg Stronghold 120 mg spot-on solution for dogs 10.1–20.0 kg Stronghold 240 mg spot-on solution for dogs 20.1–40.0 kg Stronghold 360 mg spot-on solution for dogs 40.1–60.0 kg
Stronghold 15 mg kožni nanos, raztopina za mačke in pse &lt; 2,5 kg Stronghold 30 mg kožni nanos, raztopina za pse 2,6–5,0 kg Stronghold 45 mg kožni nanos, raztopina za mačke 2,6–7,5 kg Stronghold 60 mg kožni nanos, raztopina za mačke 7,6–10,0 kg Stronghold 60 mg kožni nanos, raztopina za pse 5,1–10,0 kg Stronghold 120 mg kožni nanos, raztopina za pse 10,1–20,0 kg Stronghold 240 mg kožni nanos, raztopina za pse 20,1–40,0 kg Stronghold 360 mg kožni nanos, raztopina za pse 40,1–60,0 kg
Studies conducted in AIDS-KS patients who were taking Paxene and multiple concomitant medicinal products suggest that the systemic clearance of paclitaxel was significantly lower (p &lt; 0.05) in the presence of nelfinavir and ritonavir, but not with indinavir.
Študije, izvedene pri bolnikih z AIDS-KS, ki so sočasno prejemali zdravilo Paxene in več drugih zdravil, kažejo, da je sistemski očistek paklitaksela značilno nižji (p &lt; 0,05) ob prisotnosti nelfinavirja in ritonavirja ne pa ob prisotnosti indinavirja.
Studies in cancer patients have excluded patients with ALT or AST &gt; 2.5 x ULN (upper limit of normal) or, if due to liver metastasis, &gt; 5.0 x ULN.
V študije pri bolnikih z rakom niso bili vključeni bolniki z ALT ali AST &gt; 2,5 x ZMN (zgornjo mejo normale) oz., če je šlo za posledico metastaz jeter, &gt; 5,0 x ZMN.
Studies in rats indicated that &gt; 90% of the administered PEG was eliminated in 3 months following a single dose, with the urine being the main route of excretion.
Študije pri podganah so pokazale, da se je &gt; 90% apliciranega PEG v 3 mesecih po enkratnem odmerku izločilo z urinom, ki predstavlja glavno pot izločanja.
Studies including patients with renal insufficiency (creatinine clearance &lt; 30 ml/min for the monotherapy, and &lt; 60 ml/min for the combination regimen) have not been conducted and therefore Yondelis must not be used in this patient population (see section 4.4).
Študije, ki so vključevale bolnike z motnjami delovanja ledvic (očistek kreatinina &lt; 30 ml/min pri monoterapiji in &lt; 60 ml/min pri kombiniranem režimu) niso bile izvedene, zato zdravila Yondelis ni dovoljeno uporabiti za to populacijo bolnikov (glejte poglavje 4.4).
Studies using systemic administration of levofloxacin show that the pharmacokinetics of levofloxacin are affected by renal impairment; with decreasing renal function (estimated creatinine clearance &lt; 50 ml/min), renal elimination and clearance are decreased, and elimination half-life increased.
Študije s sistemskim dajanjem levofloksacina so pokazale, da ledvična okvara vpliva na farmakokinetiko levofloksacina; z zmanjšanim delovanjem ledvic (ocenjeni očistek kreatinina &lt; 50 ml/min) sta se ledvično izločanje in očistek zmanjšala, razpolovni čas izločanja pa se je povečal.
Study 110 was a phase II randomised, double-blind, placebo-controlled study conducted in patients with chronic genotype 1 HCV/HIV co-infection who were treatment-naïve for hepatitis C. Patients were either not on antiretroviral therapy (CD4 count ≥ 500 cells/mm3), or had stable controlled HIV (HIV RNA &lt; 50 copies/ml, CD4 count ≥ 300 cells/mm3) being treated with efavirenz or atazanavir/ritonavir in combination with tenofovir disoproxil fumarate and emtricitabine or lamivudine.
Randomizirana, dvojno slepa in s placebom nadzorovana študija faze II pri bolnikih s kroničnim HCV genotipa 1, sočasno okuženih s HIV, ki še niso prejemali zdravil proti hepatitisu C. Bolniki niso prejemali protiretrovirusnega zdravljenja (število celic CD4 ≥ 500 celic/mm3) ali so imeli stabilno, nadzorovano okužbo s HIV ( &lt; 50 kopij RNK HIV/ml, število celic CD4 ≥ 300 celic/mm3) in so se zdravili z efavirenzom ali s shemo atazanavir/ritonavir v kombinaciji s dizoproksiltenofovirat fumaratom in emtricitabinom ali lamivudinom.
Study 2 shows that 37% of the patients treated with linaclotide compared with 19% of the patients treated with placebo showed response to IBS degree of relief (p &lt; 0.0001) and 55% of the patients treated with linaclotide compared with 42% of the patients treated with placebo showed response to abdominal pain/discomfort (p=0.0002).
V študiji 2 je bila stopnja odziva olajšanja sindrom razdražljivega črevesja dosežena pri 37 % bolnikov, zdravljenih z linaklotidom, v primerjavi z 19 % bolnikov, zdravljenih s placebom (p &lt; 0,0001), odziv olajšanja abdominalne bolečine/nelagodja pa je doseglo 55 % bolnikov, zdravljenih z linaklotidom, v primerjavi z 42 % bolnikov, zdravljenih s placebom (p=0,0002).
Study AIT07 was a multicentre, open-label, randomised, phase II/III study that included 128 patients (1 to &lt; 18 years) treated with imatinib in combination with chemotherapy.
Študija AIT07 je bila multicentrična, odprta, randomizirana študija faze II/III, v katero so vključili 128 bolnikov (starih od 1 do manj kot 18 let) in jih zdravili z imatinibom v kombinaciji s kemoterapijo.
Study D-Pan H1N1-008 evaluated immunogenicity in healthy subjects (N=120) aged &gt; 60 years (stratified in ranges from 61 to 70, 71 to 80 and &gt; 80 years of age).
S klinično študijo D-Pan H1N1-008 so ocenili imunogenost pri zdravih preiskovancih (n = 120), starih več kot 60 let (razdeljenih v skupine od 61 do 70, 71 do 80 in &gt; 80 let).
Study RO-2455-404-RD was a one year study in COPD patients with a baseline (pre-bronchodilator) FEV1 &lt; 50% of predicted normal and a history of frequent exacerbations.
Študija RO-2455-404-RD je bila enoletna študija pri bolnikih s KOPB z izhodiščno (pred bronhodilatatorjem) vrednostjo FEV1 &lt; 50 % pričakovane normalne vrednosti in anamnezo pogostih poslabšanj.
Study UV I Treatment Placebo Adalimumab
Študija UV I Zdravljenje Placebo Adalimumab
Study UV II Treatment Placebo Adalimumab
Študija UV II Zdravljenje Placebo Adalimumab
Subcutaneous Xolair or placebo were administered as add-on therapy to &gt; 1,000 micrograms beclomethasone dipropionate (or equivalent) plus a long-acting beta2-agonist.
Subkutano zdravilo Xolair ali placebo so aplicirali kot dodatno zdravilo k &gt; 1.000 mikrogramov beklametazonovega dipropionata (ali ekvivalentu) in agonistu adrenergičnih receptorjev beta2 z dolgotrajnim delovanjem.
Subgroup analysis also showed that 29% of obese women (BMI ≥ 30) and 43% of normal weight women (BMI &lt; 30) showed a marked or better improvement.
V analizi podskupin se je pokazala tudi razlika med prekomerno prehranjenimi ženskami (BMI  30), kjer je prišlo do izboljšanja pri 29 % in tistimi z normalno telesno maso (BMI &lt; 30), kjer je prišlo do izboljšanja pri 43 % žensk.
Subjects (%) achieving: HbA1c &lt; 7%
Preiskovanci (%), ki so dosegli: HbA1c &lt; 7
Subjects &lt; 40 kg
Bolniki &lt; 40 kg
Subjects must have been naïve to tenofovir disoproxil fumarate, but could have received interferon based regimens ( &gt; 6 months prior to screening) or any other non-tenofovir disoproxil fumarate containing oral anti-HBV nucleoside/nucleotide therapy ( &gt; 16 weeks prior to screening).
Bolniki so morali biti predhodno še nezdravljeni z dizoproksiltenofovirijevim fumaratom, lahko pa so prejemali režime na osnovi interferona ( &gt; 6 mesecev pred presejanjem) ali katero koli drugo peroralno nukleozidno/nukleotidno zdravilo proti virusu HBV, ki ni vsebovalo dizoproksiltenofovirijevega fumarata ( &gt; 16 tednov pred presejanjem).
Subjects received 400 mg sofosbuvir and weight-based ribavirin (1,000 mg for subjects weighing &lt; 75 kg or 1,200 mg for subjects weighing ≥75 kg).
Osebe so prejele 400 mg sofosbuvirja in odmerek ribavirina na podlagi telesne mase (1.000 mg za osebe s telesno maso &lt; 75 kg ali 1.200 mg za osebe s telesno maso ≥ 75 kg).
Subjects were either not on antiretroviral therapy with a CD4+ cell count &gt; 500 cells/mm3 or had virologically suppressed HIV-1 with a CD4+ cell count &gt; 200 cells/mm3.
Osebe bodisi niso prejemale protiretrovirusne terapije s številom celic CD4+ &gt; 500 celic/mm3 ali so imele HIV-1 z virološko supresijo s številom celic CD4+ &gt; 200 celic/mm3.